DRNA NASDAQ
Dicerna Pharmaceuticals, Inc.
1W: +1.1%
1M: +0.6%
3M: +83.3%
1Y: +63.1%
3Y: +263.6%
5Y: +1153.1%
$38.22
Last traded 2021-12-27 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$164M
+587.4% ▲
5Y CAGR: +289.2%
Gross Profit
$164M
+587.4% ▲
5Y CAGR: +289.2%
Operating Income
-$113M
+11.7% ▲
Net Income
-$113M
+6.4% ▲
EPS (Diluted)
$-1.51
+14.2% ▲
EBITDA
-$111M
+7.3% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $295K | $2M | $6M | $24M | $164M |
| YoY Growth | +60.3% | +671.9% | +171.2% | +287.0% | +587.4% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $295K | $2M | $6M | $24M | $164M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D Expenses | $42M | $37M | $46M | $109M | $205M |
| SG&A Expenses | $18M | $26M | $22M | $43M | $72M |
| Operating Expenses | $60M | $63M | $67M | $152M | $278M |
| Operating Income | -$60M | -$61M | -$61M | -$128M | -$113M |
| Operating Margin | -20253.6% | -2660.8% | -991.3% | -536.3% | -68.9% |
| Interest Expense | $0 | $0 | $603K | $3K | $20K |
| Income Before Tax | -$60M | -$60M | -$89M | -$120M | -$113M |
| Tax Expense | $235K | $539K | $0 | $0 | $0 |
| Net Income | -$60M | -$60M | -$89M | -$120M | -$113M |
| Net Margin | -20173.9% | -2637.2% | -1438.7% | -503.9% | -68.6% |
| EPS (Diluted) | $-2.87 | $-2.90 | $-1.60 | $-1.76 | $-1.51 |
| EBITDA | -$59M | -$59M | -$87M | -$119M | -$111M |
| Shares Outstanding | 21M | 21M | 56M | 68M | 75M |